Buying guide · Cost / worth it / alternatives
The sticker price is the easy part of Galleri. The harder questions are what a positive result sets in motion, what a negative one is actually worth, and where the FDA and Medicare stand in October 2026. Every figure below comes from GRAIL, the FDA, the statute or the trials themselves, checked on October 15, 2026.
Galleri’s list price is $949. Through December 31, 2026, requesting it online through GRAIL’s contracted telehealth provider brings it to $699, many doctors’ offices charge $799 or less, and Function Health last listed it at $749 for members. Original Medicare and most insurers don’t pay; TRICARE does for some beneficiaries 50 and older. No price covers the scans or biopsies that follow a positive result, and the test is still waiting on an FDA decision after a 7–2 advisory panel vote on September 23, 2026.
Qualify. A defensible add-on at $699 for someone 50 or older who is current on standard screening, has extra risk and can pay for a workup. A poor buy as a replacement for colonoscopy, mammograms or lung CT, or as reassurance: in the trials it caught roughly a third of cancers diagnosed within a year, and only 14–21% of stage I cancers.
Request on galleri.com, an independent telemedicine clinician contracted by GRAIL decides whether you qualify, and you book the draw at a partner lab or at home. The cheapest route when checked, with two catches: payment plans are not available on online orders, and you still need your own doctor to run any follow-up.
Costs $100–$250 more than the online offer, but the clinician who orders the test is the one who orders the scans if it comes back positive. Ask whether the practice adds a visit fee, and ask GRAIL about its 0% payment plan for up to 12 months.
Galleri is a member-only add-on drawn at Quest. Function’s public add-on page was offline on October 15, 2026, so confirm the price in the app. Only worth it if you already want the membership: $749 plus $365 is well above GRAIL’s $699 direct offer.
For beneficiaries 50 and older with an elevated risk, such as service-related hazardous exposures, two or more first-degree relatives with cancer, or a 20-pack-year smoking history. Your provider submits the prior authorization; GRAIL’s online telehealth route is not authorized for TRICARE orders.
Fountain Life’s membership comparison lists an “Early Cancer Detection Blood Test” covering 50+ cancers, marked à la carte on some tiers, without naming the brand. Ask which test it is, whether your tier includes it, and who runs the workup if it is positive.
We checked every price on October 15, 2026 against the seller’s own page: GRAIL’s US request, pricing and FAQ pages, its TRICARE ordering guide, Function Health, Everlywell, TestWell and Hims & Hers. A price counts only if the seller publishes it. Where a page has gone offline, we say when the price was last public. Galleri.com redirects visitors outside the US, so we read the US versions of its pages.
Our criteria: what you actually pay for the test and the blood draw, who has to order it, what is left out (the follow-up workup), and whether insurance or Medicare pays. For the evidence we used the FDA’s documents for its September 23, 2026 advisory panel, the NHS-Galleri paper in the New England Journal of Medicine and GRAIL’s own trial releases, and we show where the FDA’s numbers differ from GRAIL’s. For Medicare we read the enacted statute rather than press summaries, several of which give the wrong start year.
Galleri is prescription-only, so every route runs through a clinician: your own doctor, GRAIL’s contracted telehealth provider, or a platform’s clinicians. The sample goes to GRAIL’s lab whichever way you buy. What changes is the price, and who handles a positive result.
| Route | What you pay | The catch |
|---|---|---|
| GRAIL online, via its independent telehealth provider | $699 with the Galleri Key code on galleri.com, for orders placed October 3 – December 31, 2026 | Single use, US orders only; no payment plan; the telehealth clinician decides whether you qualify |
| Your own doctor | $949 list; GRAIL says many practices charge $799 or less | Ask about visit fees; 0% payment plan for up to 12 months through GRAIL customer service |
| Function Health add-on | $749 member price when last public (August 2026), plus the $365 first-year membership | Members only; the public add-on page is offline, so confirm in the app; draw at Quest |
| Everlywell | $699 with a promo code shown on the product page; $949 without | A provider reviews the request before the order goes to Quest |
| TestWell | $949.99 plus a $6 processing fee | Physician-authorized, draw at Quest; costs more than GRAIL direct |
| Hims & Hers | Not shown on its public pages | Add-on to a Labs plan; not available in every state |
| TRICARE | Covered with prior authorization; your contractor sets any cost-sharing | Ages 50+ with an elevated risk; order through your own provider |
| GRAIL financial assistance | Up to $350 off, so at least $599 | Household income at or below 400% of the federal poverty level |
One blood draw: about 20 mL in two tubes, no fasting, at a partner lab, your doctor’s office or at home with a visiting technician. Results usually arrive about two weeks after the sample reaches GRAIL’s lab, occasionally up to four.
You get one of two answers. Nearly 99 in 100 people get “No Cancer Signal Detected.” The rest get “Cancer Signal Detected” plus one predicted Cancer Signal Origin, the organ or tissue the signal most likely came from. In GRAIL’s two big studies that prediction pointed to the right site 91–93% of the time, which is what keeps the follow-up targeted instead of a whole-body search.
GRAIL and Function both describe the test as potentially HSA and FSA eligible; confirm with your plan administrator. GRAIL does not recommend it for anyone who is pregnant, 21 or younger, or in active cancer treatment.
GRAIL’s pricing page is explicit: the cost of Galleri does not include the diagnostic testing needed to confirm cancer. A positive result is a referral, not a diagnosis. Expect imaging aimed at the predicted origin and, depending on what it shows, endoscopy or a biopsy. In PATHFINDER 2, a PET-CT was done when targeted tests did not settle the question.
In the FDA’s review of PATHFINDER 2, 159 of the 218 people worked up after a positive (72.9%) had at least one invasive procedure. Among the 90 who turned out not to have cancer, 43 (47.8%) still had one, mostly endoscopies. The median time to a final answer was 46 days, and 75 days for people whose positive turned out to be false.
Who pays for that is between you and your insurer. GRAIL notes that each insurer sets its own criteria for diagnostic tests after a Galleri result and may want prior authorization, and it offers a patient advocate if coverage is denied. We could not find a current, published dollar figure for a typical workup; it depends on the predicted origin and your plan. Before you order, know which clinician will order the scans, and check your deductible.
Two large studies sit behind Galleri: PATHFINDER 2, a prospective study without a control group of 35,878 adults 50 and older in the US and Canada, and NHS-Galleri, a randomized trial of 142,250 people aged 50 to 77 in England. Both used an earlier version of the test on participants as they enrolled. For its review, the FDA re-ran stored samples on the version GRAIL wants approved. GRAIL’s published results and the FDA’s re-test differ, so the second table shows both.
When it says cancer, it is often right. In PATHFINDER 2, 60.3% of positives led to a cancer diagnosis and specificity was 99.6%, a false-positive rate under 0.4%. Across NHS-Galleri’s three rounds, 52.0% of positives were cancer. On the FDA’s re-test, positive predictive value was 77.0% and 66.2%.
When it says no cancer, it tells you much less. Galleri caught 39.3% of all cancers diagnosed within 12 months in PATHFINDER 2 and 30.7% in NHS-Galleri, rising to 69.8% and 54.7% for 12 deadly cancer types such as pancreatic, liver and ovarian. The FDA’s figures were 35.0% and 31.6%. It detected about 11% of prostate cancers and 19–26% of breast cancers in the FDA analysis, which is one reason it cannot stand in for standard screening.
Stage is the weak spot. The FDA panel concluded that Galleri generally did not detect stage I cancers as often as later stages, and most panelists doubted the “early detection” wording in GRAIL’s proposed label.
| Stage | PATHFINDER 2 (US, Canada) | NHS-Galleri (England) |
|---|---|---|
| Stage I | 21.4% (27 of 126) | 13.6% (43 of 317) |
| Stage II | 33.3% (17 of 51) | 34.4% (54 of 157) |
| Stage III | 58.1% (18 of 31) | 44.3% (81 of 183) |
| Stage IV | 63.2% (24 of 38) | 60.0% (66 of 110) |
| All new cancers | 33.6% (90 of 268) | 31.6% (259 of 820) |
| Measure | PATHFINDER 2 | NHS-Galleri |
|---|---|---|
| Positives that were cancer (GRAIL) | 60.3% | 52.0% (three rounds) |
| Positives that were cancer (FDA re-test) | 77.0% | 66.2% |
| All cancers caught within 12 months (GRAIL) | 39.3% | 30.7% |
| All cancers caught within 12 months (FDA re-test) | 35.0% | 31.6% |
| 12 deadly cancer types caught (GRAIL) | 69.8% | 54.7% |
| Specificity (GRAIL) | 99.6% | 99.55% |
| Origin prediction correct (GRAIL) | 91.3% | 92.5% |
Not on the trial’s main measure. NHS-Galleri’s primary goal was fewer stage III and IV diagnoses across 12 prespecified cancers after three annual rounds. The result, published online in the New England Journal of Medicine on September 22, 2026, was an incidence rate ratio of 1.03 (95% CI 0.92–1.14, P = 0.63): no difference between the screened and unscreened groups.
Stage IV alone moved the right way. The key secondary endpoint came in at 0.86 (95% CI 0.74–1.00), 14% fewer stage IV cancers, and GRAIL reports the gap widened by round: 9% fewer in the first, 22% in the second and 26% in the third, the only round whose confidence interval excluded no effect. GRAIL attributes the flat primary result to extra stage III cancers found in the first round, which it says partly reflect stage IV cancers caught a step earlier.
GRAIL also reports four times as many screen-detected cancers as NHS screening alone, 16% more stage I and II diagnoses for the 12 cancer types, 21% fewer cancers found only after symptoms and 25% fewer found after an emergency presentation. Nothing has been reported yet on cancer deaths; the NEJM authors say further follow-up is warranted.
An earlier version of Galleri went on sale by prescription in June 2021 as a laboratory-developed test from GRAIL’s CLIA-certified lab, and GRAIL’s own pages still state that it has not been cleared or approved by the FDA. GRAIL filed for premarket approval on January 29, 2026, for screening adults 50 and older. When the FDA prepared for the panel, no multi-cancer screening test had FDA authorization.
On September 23, 2026, the FDA’s Molecular and Clinical Genetics Panel voted 10–0 that Galleri is reasonably safe, 6–4 that it is effective, and 7–2 with one abstention that its benefits outweigh its risks for the proposed use. Some “yes” votes on effectiveness were conditioned on dropping “early” from the indication, and the panel asked for clear labeling, shared decision-making and post-approval studies on long-term outcomes.
The FDA is not bound by the vote and had not announced a decision as of October 15, 2026; GRAIL says it expects one in the coming months. Until then, every purchase is self-pay unless you are on one of the few plans that cover it.
Original Medicare does not cover Galleri today, and GRAIL says most health insurance plans don’t either. TRICARE is the main exception: it covers beneficiaries 50 and older with an elevated cancer risk, with prior authorization through your own provider. A few Medicare Advantage plans add it as an extra; Priority Health lists a $125 or $75 copay, every two years, on two plans starting January 2027.
The law that made headlines is narrower than it sounds. The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, signed on February 3, 2026 as part of the Consolidated Appropriations Act, 2026, lets Medicare cover multi-cancer tests furnished on or after January 1, 2029. Only tests the FDA has cleared or approved qualify, and only if CMS decides through a national coverage determination that coverage is reasonable and necessary.
Even then, the statute pays for one test every 11 months, only for people 50 and older, and excludes anyone who had already turned 65 by January 1, 2029, a cutoff that rises by one year each year. In practice that covers people aging into Medicare from 2029 on, not today’s 70-year-olds, unless the US Preventive Services Task Force later gives multi-cancer screening an A or B grade, which lifts those limits. Payment is pegged to Medicare’s rate for a multi-target stool DNA test until 2031.
Consider it if you are 50 or older, already current on the screening with proven benefit (colorectal, breast, cervical, and lung CT if you qualify), and have a reason for extra vigilance, such as a heavy smoking history, a strong family history or occupational exposures. The best case is for cancers with no routine screening: the FDA panel agreed Galleri’s value is greatest there, and liver, ovarian and esophageal cancers had some of the highest detection rates in the trials.
You also need a plan for a positive: a clinician who will order the imaging, and room in your budget or deductible to pay for it. At $699 through the end of 2026, the online route is the cheapest published price, but a doctor who will own the workup can be worth the extra $100–$250.
Skip it, or wait, if you are behind on colonoscopy or a stool test, mammograms or lung screening: those come first and cost less. Skip it as reassurance, because in the trials a negative result missed about two in three cancers diagnosed within the year, and most stage I disease. Skip it if a positive would mean weeks of anxiety you are not ready for, or if the money would come out of the basics in our purchases-to-skip guide, such as blood pressure, ApoB and a real exercise plan.
If you are under 50 without specific risk factors, the test is not aimed at you: GRAIL recommends it for adults with an elevated risk, such as those 50 and older, and its FDA application covers 50 and older only.
Cancerguard, from Exact Sciences, launched in September 2025 at $689 as a laboratory-developed test for adults 50 to 84. In its development studies it reported 64% sensitivity across cancers excluding breast and prostate, with 97.4% specificity. That specificity works out to roughly 26 false positives per 1,000 people without cancer, against about 4 at Galleri’s 99.6%. GRAIL describes NHS-Galleri as the only randomized controlled trial of a multi-cancer test.
A full-body MRI is a different purchase: imaging that looks at anatomy rather than DNA in the blood, with its own incidental-finding problem and a higher price; our full-body MRI cost guide covers it. And if you are not current on colorectal screening, a stool test costs a fraction of either and has decades of evidence behind it.
The list price is $949. Through December 31, 2026, GRAIL sells it for $699 when you request it online through its contracted telehealth provider, many doctors’ offices charge $799 or less, and Function Health last listed it at $749 for members. The draw is included at GRAIL’s lab partners; follow-up tests after a positive result are not.
Yes. The $699 online offer runs from October 3 to December 31, 2026, with the Galleri Key code shown on galleri.com’s request page. GRAIL also offers up to $350 off for households at or below 400% of the federal poverty level, an ID.me discount for first responders and military, and a 0% payment plan for up to 12 months, which is not available on online orders.
Original Medicare doesn’t, and most private plans don’t. TRICARE covers it with prior authorization for beneficiaries 50 and older with an elevated risk, and some Medicare Advantage plans add it as an extra. A 2026 law lets Medicare cover FDA-approved multi-cancer tests from 2029, but only after a CMS coverage decision and only for people who had not turned 65 by January 1, 2029.
No. An FDA advisory panel voted on September 23, 2026: 7–2 with one abstention that its benefits outweigh its risks, 6–4 that it is effective and 10–0 that it is safe. The FDA had not announced a decision as of October 15, 2026. Galleri is sold as a laboratory-developed test.
It missed the main goal of NHS-Galleri, a 142,250-person randomized trial: combined stage III and IV cancers did not fall (rate ratio 1.03). Stage IV cancers were 14% lower, a key secondary result with a confidence interval of 0.74–1.00, and the drop reached 26% in the third round. No effect on cancer deaths has been reported yet.
For someone 50 or older who is current on standard screening, has extra risk and can afford a workup, $699 buys a real chance of catching a cancer that has no routine screen. It is not worth it as a substitute for colonoscopy, mammograms or lung CT, or as reassurance: it caught roughly a third of cancers diagnosed within a year in the trials, and few at stage I.
Your clinician orders tests aimed at the predicted origin: imaging, and sometimes endoscopy or a biopsy. In PATHFINDER 2, about 60% of positives proved to be cancer, the median time to an answer was 46–48 days, and nearly half of the people without cancer still had an invasive procedure. Those costs are not part of Galleri’s price.
They trade off differently. Cancerguard launched at $689 and reported higher sensitivity in development studies (64%, excluding breast and prostate) but lower specificity (97.4% against Galleri’s 99.6%), which means more false alarms. Galleri has the larger prospective studies, a randomized trial and a pending FDA application. Neither replaces standard screening.
By David Persson · Updated 2026-10-15 · Corrections: hi@agewell.guide
The Agewell Briefing
A sourced weekly read on longevity products, clinics and research, with a clear answer on what is worth trying.
One email a week. Unsubscribe with one click.
